References

cardiovascular

Кардиоваскулярная терапия и профилактика

Cardiovascular Therapy and Prevention

1728-88002619-0125

«SILICEA-POLIGRAF» LLC

10.15829/1728-8800-2013-1-95-101

cardiovascular-127

Research Article

ОБЗОРЫ

REVIEWS

ПЕРИПРОЦЕДУРНОЕ ПОВРЕЖДЕНИЕ МИОКАРДА

PERIPROCEDURAL MYOCARDIAL DAMAGE

Акинина

С. А.

Akinina

S. A.

заместитель главного врача по терапии

Тел./факс: (3467) 39–01–67, 8 (902) 819-93-79

nordcardiolog@mail.ru

Учреждение Ханты-Мансийского автономного округа — Югры, «Окружная клиническая больница», Ханты-МансийскKhanty-Mansiysk Autonomous District — Yugra, District Clinical Hospital, Khanty-Mansiysk

2013

20022013

12195101

2013

Акинина С.А.

Akinina S.A.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://cardiovascular.elpub.ru/jour/article/view/127

Реваскуляризация миокарда методом чрескожных коронарных вмешательств (ЧКВ) широко и эффективно используется для лечения ишемической болезни сердца с достижением немедленного успеха >90%. В зависимости от критериев диагностики, от 5% до 30% этих пациентов могут иметь признаки перипроцедурного повреждения миокарда (ППМ) или инфаркта миокарда (ПИМ). Предикторы развития ППМ, механизмы его появления и особенности клинической картины имеют важное значение в предупреждении ППМ. В определении и диагностике перипроцедурного некроза миокарда и ПИМ и их влияния на исходы до настоящего времени нет единой точки зрения. Согласно новейшим исследованиям, анализируемым в этом обзоре, в связи с высокой чувствительностью современных пороговых значений тропонина, возникло предложение о пересмотре современных критериев ППМ.

Percutaneous coronary intervention (PCI), as a method of myocardial revascularisation, is widely and effectively used for the treatment of coronary heart disease (CHD), with immediate success rates of >90%. Depending on the diagnostic criteria, 5–30% of these patients could develop the signs of periprocedural myocardial damage (PMD) or periprocedural myocardial infarction (PMI). PMD predictors, mechanisms of PMD development, and its specific clinical features play an important role in the PMI prevention. At present, there is no universal agreement on the definition and diagnostics of periprocedural myocardial necrosis and PMI, or on their impact on the clinical outcomes. According to the results of the recent studies, which are presented in this review, the current criteria of PMI might need to be modified, due to the increasingly high sensitivity of the modern threshold levels of troponin.

чрескожное коронарное вмешательствоперипроцедурный некроз миокардаперипроцедурный инфаркт миокарда

percutaneous coronary interventionperiprocedural myocardial necrosisperiprocedural myocardial infarction

References1

Cavallini C, Savonitto S, Violini R, et al. Impact of the elevation of biochemical markers of myocardial damage on long-term mortality after percutaneous coronary intervention: results of the CK-MB and PCI study. Eur Heart J 2005; 26: 1494–8.

Califf RM, Abdelmeguid AE, Kuntz RE, et al. Myonecrosis after revascularization procedures. JACC 1998; 31: 241–51.

Herrmann J. Peri-procedural myocardial injury: 2005 update. Eur Heart J 2005; 26: 2493–519.

Porto I, Selvanayagam JB, Van Gaal WJ, et al. Plaque volume and occurrence and location of periprocedural myocardial necrosis after percutaneous coronary intervention: insights from delayed- enhancement magnetic resonance imaging, Thrombolysis in Myocardial Infarction myocardial perfusion grade analysis, and intravascular ultrasound. Circulation 2006; 114: 662–9.

Prasad A, Herrmann J. Myocardial infarction due to percutaneous coronary intervention. N Engl J Med 2011; 364: 433–64.

Bhatt DL, Topol EJ. Does creatinine kinase-MB elevation after percutaneous coronary intervention predict outcomes in 2005? Periprocedural cardiac enzyme elevation predicts adverse outcomes. Circulation 2005; 112: 906–15.

Cutlip DE, Kuntz RE. Does creatinine kinase-MB elevation after percutaneous coronary intervention predict outcomes in 2005? Cardiac enzyme elevation after successful percutaneous coronary intervention is not an independent predictor of adverse outcomes. Circulation 2005; 112: 916–22.

Prasad A, Rihal CS, Lennon RJ, et al. Significance of periprocedural myonecrosis on outcomes after percutaneous coronary intervention: an analysis of preintervention and post- intervention troponin T levels in 5487 patients. Circ Cardiovasc Interv 2008; 1: 10–9.

Ricciardi M, Wu E, Davidson C, et al. Visualization of discrete microinfarction after percutaneous coronary interventions associated with mild creatine kinase-MB elevation. Circulation 2001; 103: 2780–3.

Selvanayagam JB, Petersen SE, Francis JM, et al. Effects of off-pump versus on-pump coronary surgery on reversible and irreversible myocardial injury: a randomized trial using cardiovascular magnetic resonance imaging and biochemical markers. Circulation 2004; 109: 345–50.

Selvanayagam JB, Porto I, Channon K, et al. Troponin elevation after percutaneous coronary intervention directly represents the extent of irreversible myocardial injury: insights from cardiovascular magnetic resonance imaging. Circulation 2005; 111: 1027–32.

Jaffe AS. Biochemical detection of acute myocardial infarction. In: Gersh B, Rahimtoola S, eds. Acute Myocardial Infarction. New York, NY: Elsevier 1991; 110–27.

Saenger AK, Jaffe AS. Requiem for a Heavyweight. The Demise of Creatine Kinase-MB. Circulation 2008; 118: 2200–6.

Mair J, Artner-Dworzak E, Dienstl A, et al. Early detection of acute myocardial infarction by measurement of mass concentration of creatine kinase-MB. Am J Cardiol 1991; 68: 1545–50.

Collinson P, Rosalki S, Kuwana T, et al. Early diagnosis of acute myocardial infarction by CK-MB mass measurements. Ann Clin Biochem 1992; 29: 43–7.

Bakker A, Gorgels J, van Vlies B, et al. The mass concentrations of serum troponin T and creatine kinase-MB are elevated before creatine kinase and creatine kinase-MB activities in acute myocardial infarction. Eur J Clin Chem Clin Biochem 1993; 31: 715–24.

Adams JE, Bodor GS, Davila-Roman VG, et al. Cardiac troponin I: a marker with high specificity for cardiac injury. Circulation 1993; 88: 101–6.

Katus HA, Remppis A, Neumann FJ, et al. Diagnostic efficiency of troponin T measurements in acute myocardial infarction. Circulation 1991; 83: 902–12.

Adams JE, Schechtman KB, Landt Y, et al. Comparable detection of acute myocardial infarction by creatine kinase MB isoenzyme and cardiac troponin I. Clin Chem 1994; 40: 1291–5.

Apple FS, Falahati A, Paulsen PR, et al. Improved detection of minor ischemic myocardial injury with measurement of serum cardiac troponin I. Clin Chem 1997; 43: 2047–51.

Tanaka H, Abe S, Yamashita T, et al. Serum levels of cardiac troponin I and troponin T in estimating myocardial infarct size soon after reperfusion. Coron Artery Dis 1997; 8: 433–9.

Alpert J, Thygesen K, Antman E, et al. Myocardial Infarction Redefined — a consensus document of The Joint European Society of Cardiology/ American College of Cardiology Committe. JACC 2000; 36: 959–69.

Grines CL, Dixon S. A nail in the coffin of troponin measurements after percutaneous coronary intervention. JACC 2011; 57: 662–3.

Thygesen K, Alpert JS, White HD, on behalf of Joint European Society of Cardiology/American College of Cardiology/American Heart Association/ World Heart Federation Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Circulation 2007; 22: 2634–53.

2009 Focused Updates: ACC/AHA Guidelines for the Management of patients with ST — elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update). JACC 2009; 54: 2205–41.

Detre K, Holubkov R, Cowley M, et al. Percutaneous transluminal coronary angioplasty in 1985–1986 and 1977–1981. The National Heart, Lung, and Blood Institute Registry. N Engl J Med 1988; 318: 265–70.

Johansen O, Brekke M, Stromme J, et al. Myocardial damage during percutaneous transluminal coronary angioplasty as avidenced by troponin T measurements. Eur Heart J 1998; 19: 112–7.

Remppis A, Ehlermann P, Giannitsis E, et al. Cardiac troponin T levels at 96 hours reflect myocardial infarct size: a pathoanatomical study. Cardiology 2000; 93: 249–53.

Ricciardi MJ, Wu E, Davidson CJ, et al. Visualization of discrete microinfarction after percutaneous coronary intervention associated with mild creatine kinase-MB elevation. Circulation 2001; 103: 2780–3.

Natarajan MK, Kreatsoulas C, Velianou JL, et al. Incidence, predictors, and clinical significance of troponin-I elevation without creatine kinase elevation following percutaneous coronary interventions. Am J Cardiol 2004; 93: 750–3.

Gruberg L, Dangas G, Metran R, et al. Clinical outcome following percutaneous coronary interventions in patients with chronic renal failure. Catheter Cardiovasc Interv 2002; 55: 66–72.

McKechnie RC, Smith D, Montoye C, et al. Prognostic implication of anemia on in-hospital outcomes after percutaneous coronary intervention. Circulation 2004; 110: 271–7.

Kini A, Marmur JD, Kini S, et al. Creatine kinase-MB elevation after coronary intervention correlates with diffuse atherosclerosis, and low-tomedium level elevation has a benign clinical course: implications for early discharge after coronary intervention. JAСC 1999; 34: 663–71.

Fujii K, Carlier SG, Mintz GS, et al. Creatine kinase-MB enzyme elevation and long-term clinical events after successful coronary stenting in lesions with ruptured plaque. Am J Cardiol 2005; 95: 355–9.

Motmani JC, Topol EJ. Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation 1998; 97: 916–31.

Ashby DT, Dangas G, Aymong EA, et al. Effect of percutaneous coronary interventions for in-stent restenosis in degenerated saphenous vein grafts without distal embolic protection. JAСC 2003; 41: 749–52.

Wolfram R, Ledorgne L, Cheneau E, et al. Comparison of creatine kinase elevation and outcome of percutaneous coronary interventions for saphenous vein grafts in-stent restenosis versus de novo stenosis. Am J Cardiol 2003; 92: 980–3.

Mandadi VR, DeVoe MC, Ambrose JA, et al. Predictors of troponin elevation after percutaneous coronary intervention. Am J Cardiol 2004; 93: 747–50.

Ledorgne L, Cheneau E, Pichard A, et al. Effect of direct stenting on clinical outcome in patients treated with percutaneous coronary interventions on saphenous vein grafts. A Heart J 2003; 146: 501–6.

Ballarino MA, Moreyra EJr, Damonte A, et. al. Multicenter randomized comparison of direct vs. conventional stenting the DIRECTO trial. Catheter Cardiovasс Interv 2003; 58: 434–40.

Prasad A, Gersh BJ, Bertrand ME, et al. Prognostic significance of periproce- dural versus spontaneously occurring myocardial infarction after percutaneous coronary intervention in patients with acute coronary syndromes: an analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. JACC 2009; 54: 477–86.

Hong YJ, Mintz GS, Kim SW, et al. Impact of plaque composition on cardiac troponin elevation after percutaneous coronary intervention: an ultrasound analysis. JACC Cardiovasc Imaging 2009; 2: 458–68.

Uetani T, Amano T, Ando H, et al. The correlation between lipid volume in the target lesion, measured by integrated backscatter intravascular ultrasound, and post-procedural myocardial infarction in patients with elective stent implantation. Eur Heart J 2008; 29: 1714–20.

Bahrmann P, Werner GS, Heusch G, et al. Detection of coronary microembolization by Doppler ultrasound in patients with stable angina pectoris undergoing elective percutaneous coronary interventions. Circulation 2007; 115: 600–8.

Kini AS, Lee P, Duffy ME, et al. Postprocedure chest pain after coronary stenting: implications on clinical restenosis. JACC 2003; 33–8.

Robbins MA, Marso SP, Wolski K, et al. Сhest pain — strong predictor of adverse cardiac events following percutaneous intervention (from the Evalution of Platelet IIb/IIIa inhibitor for Stenting Trial (EPISTENT). Am J Cardiol 1999; 84: 1350–3.

Stone GW, Mehran R, Dangas G, et al. Differential impact on survival of electrocar- diographic Q-wave versus enzymatic myocardial infarction after percutaneous intervention: a device-specific analysis of 7147 patients. Circulation 2001; 104: 642–7.

Ellis SG, Chew D, Chan A, et al. Death following creatine kinase-MB elevation after coronary intervention: identification of an early risk period: importance of cre- atine kinase-MB level, completeness of revascularization, ventricular function, and probable benefit of statin therapy. Circulation 2002; 106: 1205–10.

Kugelmass AD, Cohen DJ, Moscucci M, et al. Elevation of the creatine kinase myocardial isoform following otherwise successful directional coronary atherectomy and stenting. Am J Cardiol 1994; 74: 748–54.

Abdelmeguid AE, Topol EJ, Whitlow PL, et al. Significance of mild transient release of creatine kinase- MB fraction after percutaneous coronary interventions. Circulation 1996; 94: 1528–36.

Kong TQ, Davidson CJ, Meyers SN, et al. Prognostic implication of creatine kinase elevation following elective coronary artery interventions. JAMA 1997; 277: 461–6.

Saucedo JF, Mehran R, Dangas G, et al. Long-term clinical events following creatine kinase-myocardial band isoenzyme elevation after successful coronary stenting. JACC 2000; 35: 1134–41.

Jeremias A, Baim DS, Ho KK, et al. Differential mortality risk of postprocedural creatine kinase-MB elevation following successful versus unsuccessful stent procedures. JACC 2004; 44: 1210–4.

Topol EJ, Mark DB, Lincoff AM, et al. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blocade in patients undergoing coronary stenting: results from a multicentre randomized trial. EPISTENT Investigators. Lancet 1999; 354: 2019–24.

Lincoff AM, Tcheng JE, Califf RM, et al. Sustained suppression of ischemic complications of coronary intervention by GP IIb/IIIa blocade with abciximab: one-year outcome in EPILOG trial. Evaluatoin in PTCA to improve long-term outcome with abciximab GP IIb/IIIa blocade. Circulation 1999; 99: 1951–8.

Topol EJ, Ferguson JJ, Weisman HF, et al. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blocade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of platelet IIb/IIIa inhibition for prevention of ischemic complication. JAMA 1997; 278: 479–84.

Nienhuis MB, Ottervanger JP, Bilo HJG, et al. Prognostic value of troponin after elective percutaneous coronary intervention: a meta-analysis. Cath Cardiovasc Intervent 2008; 71: 318–24.

Kizer JR, Muttrej MR, Matthai WH, et al. Role of cardiac troponin T in the long-term risk stratification of patients undergoing percutaneous coronary intervention. Eur Heart J 2003; 24: 1314–22.

Nienhuis MB, Ottervanger JP, Bilo HJ, et al. Prognostic value of troponin after elective percutaneous coronary intervention: a meta-analysis. Catheter Cardiovasc Interv 2008; 71: 318–24.

Testa L, Van Gaal WJ, Biondi Zoccai GG, et al. Myocardial infarction after percutaneous coronary intervention: a meta-analysis of troponin elevation applying the new universal definition. QJM 2009; 102: 369–78.

Prasad A, Singh M, Lerman A, Lennon RJ, et al. Isolated elevation in troponin T after percutaneous coronary intervention is associated with higher long-term mortality. JACC 2006; 48: 1765–70.

Nallamothu BK, Chetcuti S, Mukher-jee D, et al. Prognostic implication of troponin I elevation after percutaneous coronary intervention. Am J Cardiol 2003; 91: 1272–4.

Feldman DN, Minutello RM, Bergman G, et al. Relation of troponin I levels following nonemergent percutaneous coronary intervention to short- and long-term outcomes. Am J Cardiol 2009; 104: 1210–5.

Cantor WJ, Newby LK, Christenson RH, et al. Prognostic significance of elevated troponin I after percutaneous coronary intervention. JACC 2002; 39: 1738–44.

Kini AS, Lee P, Marmur JD, et al. Correlation of postpercutaneous coronary intervention creatine kinase-MB and tro- ponin I elevation in predicting mid-term mortality. Am J Cardiol 2004; 93: 18–23.

De Labriolle A, Lemesle G, Bonello L, et al. Prognostic significance of small tro- ponin I rise after a successful elective percutaneous coronary intervention of a native artery. Am J Cardiol 2009; 103: 639–45.

Cavallini C, Verdecchia P, Savonitto S, et al. Prognostic value of elevation after percutaneous coronary intervention. Circ Сardiovasc Interv 2010; 3: 431–5.

Jeremias A, Kleiman NS, Nassif D, et al. Prevalence and prognostic significance of preprocedural cardiac troponin elevation among patients with stable coronary artery disease undergoing percutaneous coronary intervention: results from the Evaluation of Drug Eluting Stents and Ischemic Events registry. Circulation 2008; 118: 632–8.

Hamm CW, Ravkilde J, Gerhardt W, et al. The prognostic value of serum troponin T in unstable angina. N Engl J Med 1992; 327: 146–50.

Lim CCS, van Gaal WJ, Testa L, et al. With the ‘universal definition,’ measurement of creatine kinase-myocardial band rather than troponin allows more accurate diagnosis of periprocedural necrosis and infarction after coronary intervention. JACC 2011; 57: 653–61.

Bhatt DL, Lincoff AM, Gibson CM, et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 2009; 361: 2330–41.

Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007; 115: 2344–51.

Vranckx P, Cutlip DE, Mehran R, et al. Myocardial infarction adjudication in contemporary all-comer stent trials: balancing sensitivity and specificity. Eur Intervention 2010; 5: 4.

The authors declare that there are no conflicts of interest present.